Datos personales

Mi foto
Medico Especialista Consultor en Urología. Egresado de la UNR (Universidad Nacional de Rosario) Médico de Staff servicio de urología. Hospital Privado de Comunidad. Mar del Plata. Coordinador sector Medicina Sexual. Coordinador sector cirugía reconstructiva de uretra. Educador sexual DIEGEP Nº 3283/96 Miembro de SLAMS (Soc. Latinoamericana de Medicina Sexual) Miembro de ISSM (International Society of sexual Medicine) Miembro del capítulo Medicina sexual SAU (Soc. Arg. de Urología) Vicepresidente AMSI (Asoc. Marplatense de Sexualidad Integral)

lunes, 14 de abril de 2014

TRASTORNOS EYACULATORIOS EN TRATAMIENTO DEL PROSTATISMO

   Recientemente publicado en el Congreso Europeo de Urologia, el articulo alude a los trastornos eyaculatorios causados por las drogas utilizadas para el tratamiento de la hiperplasia prostatica benigna (HPB) y fue extraido de la pagina oficial de la AUA (American Urological Association)
   Cabe mencionar que todos estos trastornos son reversibles con solo abandonar el uso de la droga, e incluyen: retroeyaculacion, disminucion del volumen ayaculatorio, sensacion de displacer en el momento de la eyaculacion hasta anorgasmia. El final del articulo se refiere a la combinacion mas usada en la actualidad para el tratamiento de los sintomas prostaticos: TAMSULOSINA mas DUTASTERIDE

Ejaculatory Problems Linked to BPH Drugs

 
ECO: New Weight Loss Drug Effective in Advanced Obesity
Alpha blockers and 5-alpha reductase inhibitors increase the risk of ejaculatory dysfunction.
STOCKHOLM—Medications used to treat benign prostatic hyperplasia (BPH) may increase the risk of ejaculatory dysfunction (EjD), according to study findings presented at the European Association of Urology 29th annual congress.
Mauro Gacci, MD, of the University of Florence in Italy, and colleagues conducted a systematic review and meta-analysis of data from 30,000 patients enrolled in randomized controlled trials showing that alpha blockers increased the risk of EjD nearly 6-fold compared with placebo. The increase in EjD risk varied by alpha blocker. Silodosin and tamsulosin were associated with a 32.5 times and 8.6 times increased risk versus placebo, whereas doxazosin and terazosin did not differ significantly from placebo.
Results also showed that use of 5-alpha reductase inhibitors (5ARIs) was associated with a significant 2.7 times increased risk of EjD compared with placebo. Finasteride and dutasteride were associated with similar EjD risk. The risk of EjD did not differ significantly between alpha blockers and 5ARIs.
Combination therapy with both alpha blockers and 5ARIs was associated with a 3-fold increased risk compared with either drug class alone.

No hay comentarios:

Publicar un comentario

Nota: solo los miembros de este blog pueden publicar comentarios.